Actor Swwapnil Joshi has been roped in as the brand ambassador for elimination of lymphatic filariasis in Maharashtra by the state government's Public Health department.
Lymphatic filariasis impairs the lymphatic system and can lead to the abnormal enlargement of body parts, causing pain, severe disability and social stigma.
Over 31 million people in India are estimated to be infected with filariasis and over 29 million suffer from disability associated with the disease. As of 2017, Maharashtra recorded 65,155 cases of filariasis, read a statement on Wednesday.
The Maharashtra government, under the National Programme for Elimination of Lymphatic Filariasis, will undertake Mass Drug Administration (MDA) in Nagpur from January 20.
This MDA round will also mark the roll-out of the new Triple Drug Therapy to accelerate lymphatic filariasis elimination efforts. A third drug called Ivermectin will be added to the usual combination of two drugs - Diethylcarbamazine Citrate and Albendazole.
"The time has come to make this ancient scourge a history. I am honoured to be able to contribute to this cause. 'Hathi rog' is an entirely preventable disease. But few people know that. I wish to be able to play my part in changing the situation by encouraging people to have the government-administered medicines," Swwapnil said.
"It is up to us, the people, to ensure that Maharashtra, and India, is free of filariasis," he added.
In an official letter acknowledging Swwapnil as lymphatic filariasis champion, Joint Director of Health Services P.B. Bhoi, said: "You are among the most influential personalities in the state of Maharashtra. Your influence will not only help in creating awareness but will also instil confidence in masses toward the government-supported Mass Drug Administration programme."
--IANS
nn/rb/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
